These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23183895)

  • 21. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons.
    Mazzoli S; Lopalco L; Salvi A; Trabattoni D; Lo Caputo S; Semplici F; Biasin M; Bl C; Cosma A; Pastori C; Meacci F; Mazzotta F; Villa ML; Siccardi AG; Clerici M
    J Infect Dis; 1999 Sep; 180(3):871-5. PubMed ID: 10438383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.
    Moja P; Tranchat C; Tchou I; Pozzetto B; Lucht F; Desgranges C; Genin C
    J Infect Dis; 2000 May; 181(5):1607-13. PubMed ID: 10823760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples.
    Choi RY; Levinson P; Guthrie BL; Lohman-Payne B; Bosire R; Liu AY; Hirbod T; Kiarie J; Overbaugh J; John-Stewart G; Broliden K; Farquhar C
    AIDS; 2012 Nov; 26(17):2155-63. PubMed ID: 22948273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells.
    Devito C; Broliden K; Kaul R; Svensson L; Johansen K; Kiama P; Kimani J; Lopalco L; Piconi S; Bwayo JJ; Plummer F; Clerici M; Hinkula J
    J Immunol; 2000 Nov; 165(9):5170-6. PubMed ID: 11046049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A.
    Wright A; Lamm ME; Huang YT
    J Virol; 2008 Dec; 82(23):11526-35. PubMed ID: 18829757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.
    Kozlowski PA; Chen D; Eldridge JH; Jackson S
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):813-22. PubMed ID: 7986587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis.
    Wills S; Hwang KK; Liu P; Dennison SM; Tay MZ; Shen X; Pollara J; Lucas JT; Parks R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Thomas R; Kim JH; Michael NL; Robb ML; McRaven M; Montefiori DC; Hope TJ; Liao HX; Moody MA; Ferrari G; Haynes BF; Alam SM; Bonsignori M; Tomaras GD
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
    Hioe CE; Xu S; Chigurupati P; Burda S; Williams C; Gorny MK; Zolla-Pazner S
    Int Immunol; 1997 Sep; 9(9):1281-90. PubMed ID: 9310831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
    Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
    J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
    Front Immunol; 2018; 9():244. PubMed ID: 29651286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative assessment of masking of neutralization epitopes in HIV-1.
    Agarwal A; Hioe CE; Swetnam J; Zolla-Pazner S; Cardozo T
    Vaccine; 2011 Sep; 29(39):6736-41. PubMed ID: 21216319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
    J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
    Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
    J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.
    Özkaya Şahin G; Månsson F; Palm AA; Vincic E; da Silva Z; Medstrand P; Norrgren H; Fenyö EM; Jansson M
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):470-8. PubMed ID: 23088167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins.
    Kozlowski PA; Jackson S
    AIDS Res Hum Retroviruses; 1992 Oct; 8(10):1773-80. PubMed ID: 1457191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses.
    Tay MZ; Liu P; Williams LD; McRaven MD; Sawant S; Gurley TC; Xu TT; Dennison SM; Liao HX; Chenine AL; Alam SM; Moody MA; Hope TJ; Haynes BF; Tomaras GD
    PLoS Pathog; 2016 Aug; 12(8):e1005817. PubMed ID: 27579713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies.
    Fouda GG; Yates NL; Pollara J; Shen X; Overman GR; Mahlokozera T; Wilks AB; Kang HH; Salazar-Gonzalez JF; Salazar MG; Kalilani L; Meshnick SR; Hahn BH; Shaw GM; Lovingood RV; Denny TN; Haynes B; Letvin NL; Ferrari G; Montefiori DC; Tomaras GD; Permar SR;
    J Virol; 2011 Sep; 85(18):9555-67. PubMed ID: 21734046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.